Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LNA043 for Knee Cartilage Regeneration in ACI Patients
NCT03334812Phase 2Terminated
- Sponsor
- Novartis
- Start
- Oct 2017
- Primary completion
- Apr 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of LNA043 in Articular cartilage defect, sponsored by Novartis. Started Oct 2017; status: terminated.
02
Drugs
LNA043
03
Conditions
Articular cartilage defect
Beyond the preview
Go deeper on NCT03334812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03334812.